CTP-347

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C19H20FNO3
Molecular Weight	331.3777
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[2H]C1([2H])OC2=CC=C(OC[C@@H]3CNCC[C@H]3C4=CC=C(F)C=C4)C=C2O1

InChI

InChIKey=AHOUBRCZNHFOSL-SVLNYFRSSA-N

InChI=1S/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2/t14-,17-/m0/s1/i12D2

HIDE SMILES / InChI

Molecular Formula	C19H20FNO3
Molecular Weight	331.3777
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 15:21:13 GMT 2023` Edited by `admin` on `Sat Dec 16 15:21:13 GMT 2023`
Record UNII	KP3VT00O7V
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CTP-347

Common Name

English

PIPERIDINE, 3-((1,3-BENZODIOXOL-5-YL-2,2-D2-OXY)METHYL)-4-(4-FLUOROPHENYL)-, (3S,4R)-

Common Name

English

D2-PAROXETINE

Common Name

English

Code System Code Type Description

CAS

923932-43-8

Created by admin on Sat Dec 16 15:21:13 GMT 2023 , Edited by admin on Sat Dec 16 15:21:13 GMT 2023

PRIMARY

PUBCHEM

58946140

Created by admin on Sat Dec 16 15:21:13 GMT 2023 , Edited by admin on Sat Dec 16 15:21:13 GMT 2023

PRIMARY

FDA UNII

KP3VT00O7V

Created by admin on Sat Dec 16 15:21:13 GMT 2023 , Edited by admin on Sat Dec 16 15:21:13 GMT 2023

PRIMARY

EPA CompTox

DTXSID201134995

Created by admin on Sat Dec 16 15:21:13 GMT 2023 , Edited by admin on Sat Dec 16 15:21:13 GMT 2023

PRIMARY

Related Record Type Details


					CJZ26L1EGI

SODIUM-DEPENDENT SEROTONIN TRANSPORTER

TARGET -> INHIBITOR


					41VRH5220H

PAROXETINE

NON-LABELED -> LABELED

Related Record Type Details


					KP3VT00O7V

CTP-347

ACTIVE MOIETY

Name	Property Type	Parameters
MAXIMUM TOLERATED DOSE	TOXICITY	SOCIAL PHOBIA: 37.5 mg/day (CONTROLLED-RELEASE TABLET) OBSESSIVE-COMPULSIVE DISORDER: 60 mg/day (FDA DOSAGE) (IMMEDIATE-RELEASE TABLET AND SUSPENSION) OBSESSIVE-COMPULSIVE DISORDER: 60 -100 mg/day (GUIDELINE DOSAGE) (RAPID METABOLIZERS OR THOSE WITH INADEQUATE RESPONSE AFTER 8 WEEKS) PANIC DISORDER: 60 mg/day (IMMEDIATE-RELEASE TABLET AND SUSPENSION) MAJOR DEPRESSIVE DISORDER: 62.5 mg/day (CONTROLLED-RELEASE TABLET) PANIC DISORDER: 75 mg/day (CONTROLLED-RELEASE TABLET)

Route of Elimination	PHARMACOKINETIC	EXCRETED UNCHANGED

Tmax	PHARMACOKINETIC

Volume of Distribution	PHARMACOKINETIC

Biological Half-life	PHARMACOKINETIC

PROTEIN BINDING	PHARMACOKINETIC

Tmax	PHARMACOKINETIC

Route of Elimination	PHARMACOKINETIC	EXCRETED UNCHANGED